Lupeol compound is a cyclic triterpene alcohol that is widely found in plants. The compound lupeol has been reported to exhibit antitumor, anti-inflammatory, anxiolytic, neuroprotective and hepatoprotective effects. Recent research shows that lupeol could be a potential medicine for various diseases and also an adjuvant for intractable diseases. Cancer poses a health threat that is increasingly common around the world. Among new cancer cases, lung cancer is one of the most common and deadly cancers worldwide. In this study, the anticancer efficiency of lupeol on human lung adenocarcinoma A549 and glioma C6 cell lines were examined. Various concentrations of lupeol (500, 250, 125, 62.5, 31.25, 15.62, 7.81, 3.90 μM) effectually reduced cell viability in the A549 and C6 cell lines in a dose-dependent manner. These results showed that lupeol had selective anticancer activity against A549 and C6 cell lines.
| Primary Language | English |
|---|---|
| Subjects | Pharmacology and Pharmaceutical Sciences (Other) |
| Journal Section | Research Article |
| Authors | |
| Submission Date | April 7, 2024 |
| Acceptance Date | April 22, 2024 |
| Publication Date | April 30, 2024 |
| DOI | https://doi.org/10.55971/EJLS.1466309 |
| IZ | https://izlik.org/JA96RT72GF |
| Published in Issue | Year 2024 Volume: 3 Issue: 1 |
Announcement
Dear Readers, Authors, and Reviewers,
An inconsistency has been identified in the automatically generated editorial board information due to a technical issue in the infrastructure that enables the electronic management of our journal. As a result of this technical problem, the current editorial board information can be accessed on DergiPark at https://dergipark.org.tr/en/pub/ejls/board.
However, the editorial board and reviewer information for a published issue are included in the PDF file of the relevant issue. Therefore, the accurate and authoritative information should be accessed through the PDF of the respective issue.
For your information.
**Click here for an important announcement regarding the Editorial Board.**